Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
08:05am, Monday, 26'th Feb 2024
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing nove
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 31'st Jan 2024
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments i
Spero Therapeutics Provides Corporate Update and 2024 Outlook
08:05am, Friday, 05'th Jan 2024
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients
$95 million in development milestones payable over two years, as part of GSK license agreement $95 million in development milestones payable over two years, as part of GSK license agreement
Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript
07:05pm, Monday, 13'th Nov 2023
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath S
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
08:05am, Monday, 06'th Nov 2023
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) on b
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
08:05am, Wednesday, 01'st Nov 2023
Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations. Ms. Rajavelu brings over two decades of experience i
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 31'st Oct 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy
01:32pm, Wednesday, 18'th Oct 2023
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NEW YORK , Oct. 11, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim
Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference
04:05pm, Wednesday, 20'th Sep 2023
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and co
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
08:05am, Wednesday, 06'th Sep 2023
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and co
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:31pm, Tuesday, 29'th Aug 2023
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for August 29th
09:01am, Tuesday, 29'th Aug 2023
SPRO, FBIZ, KNSL, BMI and FDUS have been added to the Zacks Rank #1 (Strong Buy) List on August 29, 2023.
